Topics Engaged In
-
- Topic
- Voices
- Last Post
-
-
ASCO/NCCN guidlines now out
Started by:
in: Side-effect management
- 5
- October 14, 2018 at 5:40 am
-
New BRAF/MEK inhibitors coming to market
Started by:
in: Dosing and administration
- 7
- October 8, 2018 at 10:07 am
-
Nivolumab dosing and Medicare
Started by:
in: Reimbursement
- 7
- July 23, 2018 at 4:02 pm
-
Variants to mutations; fusions and
Started by:
in: Other
- 5
- June 25, 2018 at 8:58 am
-
Herbal medications
Started by:
in: Alternative/complementary therapies
- 5
- June 22, 2018 at 7:29 pm
-
Pembro plus Epacadostat
Started by:
in: Other
- 6
- June 11, 2018 at 2:29 pm
-
BRAF testing for adjuvant therapy
Started by:
in: Other
- 6
- June 3, 2018 at 6:18 am
-
Adjuvant targeted therapy
Started by:
in: Other
- 4
- May 11, 2018 at 9:44 pm
-
Adjuvant Immunotherapy in stage IIIA patients
Started by:
in: Expectations for therapy
- 7
- May 5, 2018 at 8:59 pm
-
Must be an app for that
Started by:
in: Other
- 3
- April 27, 2018 at 11:27 pm
-
ICI atypical rash
Started by:
in: Side-effect management
- 4
- April 26, 2018 at 12:25 am
-
Skin sensitivity
Started by:
in: Side-effect management
- 5
- April 26, 2018 at 12:04 am
-
PET/CT scans
Started by:
in: Other
- 7
- April 13, 2018 at 5:00 pm
-
Hypercalcemia
Started by:
in: Side-effect management
- 4
- April 8, 2018 at 3:42 pm
-
Survivorship plans
Started by:
in: Coordination of care
- 7
- March 29, 2018 at 9:39 pm
-
ASCO/NCCN guidlines now out